GHRP-2
LongevityHealthspan-relevant evaluation of GHRP-2 starts with mapping its mechanism to the hallmarks of aging and asking which of the nine hallmarks its primary pharmacology engages. Selective ghrelin/GHSR receptor agonist on pituitary somatotrophs Stimulates a pulsatile GH release. Mildly raises ACTH/cortisol and prolactin compared to ipamorelin.. The ~15-60 min pharmacokinetic profile, the cycle-based 100-300 mcg 2-3x daily subq dosing pattern, and the longevity-specific stack partners on adjacent hallmarks together produce the framework documented below.
Key Takeaways
Longevity lens: GHRP-2 maps to specific hallmarks-of-aging endpoints rather than to acute clinical markers. Mechanism: Selective ghrelin/GHSR receptor agonist on pituitary somatotrophs. Healthspan biomarkers: epigenetic age, telomere length, inflammatory markers, metabolic flexibility - all tracked across pre-post cycles. Longevity protocol: cycle-based 100-300 mcg 2-3x daily subq dosing; 8-12 week cycles favoured over continuous administration. Longevity stack partners: Epithalon, Thymalin, NAD+.
Selective ghrelin/GHSR receptor agonist on pituitary somatotrophs. Stimulates a pulsatile GH release. Mildly raises ACTH/cortisol and prolactin compared to ipamorelin. Healthspan-relevant interpretation of this mechanism asks which biomarkers move, in which direction, on what timescale. The subsections below cover the hallmark mapping, cellular and transcriptional effects, biomarker tracking, and the cycle structure favoured in longevity-research protocols for GHRP-2.
Mapping to the hallmarks of aging
GHRP-2's longevity relevance is best evaluated by mapping its mechanism to the hallmarks-of-aging framework. Selective ghrelin/GHSR receptor agonist on pituitary somatotrophs. Stimulates a pulsatile GH release. Mildly raises ACTH/cortisol and prolactin compared to ipamorelin. This places its dominant contribution in the integrative hallmarks (systemic and inflammatory) layer of the framework, with secondary effects on adjacent hallmarks that combine to produce the broader healthspan-relevant phenotype.
Cellular reprogramming and gene expression
Where GHRP-2 has measurable effects on transcriptional programmes, the direction of effect tends to be toward younger phenotypes rather than away from them. This signature — partial reversal of age-associated expression changes — is what distinguishes a true longevity-relevant compound from a symptomatic one. The signal strength varies, but the direction is what longevity researchers track.
Healthspan markers and biological age
For users measuring epigenetic age, telomere length, or composite biological-age markers (Horvath, PhenoAge, GrimAge) before and after GHRP-2 cycles, the question is whether the intervention measurably moves these markers. Current evidence varies by compound but the framework for evaluation is shared: paired pre-post measurement with appropriate inter-test interval.
For senescence modulation as a longevity-relevant endpoint, GHRP-2 is typically run in cycle-based protocols with paired pre-post biomarker measurement. Epigenetic age tracking, telomere length, and inflammatory panels are the standard outcome measures.
Telomere Support maps to one of the hallmarks of aging and is one of the dimensions on which GHRP-2 is evaluated in the longevity literature. Effect size on biomarkers varies across studies; the consistent finding is direction-of-effect rather than dramatic magnitude.
GHRP-2's contribution to healthspan extension as a longevity dimension is incremental rather than dramatic, consistent with the broader picture of healthspan-relevant peptides. The compound is best understood as one layer in a multi-component longevity protocol.
For nutrient sensing as a longevity-relevant endpoint, GHRP-2 is typically run in cycle-based protocols with paired pre-post biomarker measurement. Epigenetic age tracking, telomere length, and inflammatory panels are the standard outcome measures.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 100-300 mcg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 60-300 mcg | 4–6 weeks initial cycle |
| Longevity focus | SubQ | 100-300 mcg | 2-3x daily SubQ |
| Maintenance phase | SubQ | 70-300 mcg | Ongoing with periodic pauses |
Dose timing for GHRP-2 is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
GHRP-2 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from longevity researchers.
- GHRP-2 + Epithalon: Identified by Khavinson in St. Pairs naturally with GHRP-2's mechanism in longevity / hallmarks of aging protocols.
- GHRP-2 + Thymalin: Influences T-cell maturation and immune function. Pairs naturally with GHRP-2's mechanism in longevity / hallmarks of aging protocols.
- GHRP-2 + NAD+: Coenzyme for over 500 enzymatic reactions including oxidative phosphorylation, glycolysis, fatty acid β-oxidation, and the citric acid cycle. Pairs naturally with GHRP-2's mechanism in longevity / hallmarks of aging protocols.
- GHRP-2 + MOTS-c: Translocates to the nucleus under metabolic stress and activates AMPK signalling. Pairs naturally with GHRP-2's mechanism in longevity / hallmarks of aging protocols.
More prolactin/cortisol effect than ipamorelin. Pair with GHRH for synergy.
Lens-specific safety considerations for longevity / hallmarks of aging use of GHRP-2: More prolactin/cortisol effect than ipamorelin. Pair with GHRH for synergy. Additional longevity / hallmarks of aging monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| GHRP-2 | Growth hormone releasing peptide | ~15-60 min | Longevity |
| Epithalon | Pineal-derived tetrapeptide | Very short (minutes) | A pineal-derived tetrapeptide best known for telomerase upregulation and pineal-gland melatonin restoration in long-running rodent and human studies |
| Thymalin | Thymic polypeptide extract | Variable | A complex of low-molecular-weight thymic polypeptides used in Russian clinical research for decades — immunomodulation, anti-aging, and supportive care in chronic disease |
| MOTS-c | Mitochondrially-encoded peptide | Hours; tissue-distributed | A 16-amino-acid peptide encoded within mitochondrial DNA — discovered in 2015 and shown to regulate metabolic homeostasis, AMPK signalling, and insulin sensitivity |
| GHK-Cu | Tripeptide-copper complex | ~30 min plasma | A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression |
When in life should I start GHRP-2?
Cycle-based or continuous dosing for longevity?
Does GHRP-2 interact with rapamycin, metformin, or other longevity stacks?
Does GHRP-2 actually extend lifespan?
How does GHRP-2's half-life affect dosing?
What route should I use for GHRP-2?
Start a GHRP-2 Protocol
Alukard provides physician-supervised longevity protocols with GMP-certified GHRP-2 and GMP-certified compounds with biological age testing and healthspan markers.
Get ProtocolQuick Facts
- Molecular weight
- 817 Da
- Sequence length
- 6 aa
- Half-life
- ~15-60 min
- WADA
- Banned (S2)
- FDA
- Approved in Japan for GH stimulation testing only
All longevity / hallmarks of aging applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for GHRP-2 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Longevity / Hallmarks of Aging Protocol for GHRP-2
Alukard provides physician-supervised longevity protocols with GMP-certified compounds with biological age testing and healthspan markers.
HIPAA Compliant · GMP Certified · Physician Supervised